Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.


Abstract

Our results clearly showed the antitumor activity of MLN2238 in a variety of mouse models of B-cell lymphoma and PCM, supporting its clinical development. MLN9708 is being evaluated in multiple phase I and I/II trials.


Full Text

  • DOI - Clinical cancer research : an official journal of the American Association for Cancer Research (DOI)
  • HighWire Press - full-text online

Subjects


Similar articles

Español | English

© Galenicom 1999-2013